• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Adlai Nortye Ltd. - American Depositary Shares (NQ:ANL)

    9.960 +0.470 (+4.95%)
    Streaming Delayed Price Updated: 10:52 AM EDT, Jul 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Adlai Nortye Ltd. - American Depositary Shares

    News headline image
    Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye to Participate in Upcoming Investor Conferences
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
    Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of Directors 
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    News headline image
    Adlai Nortye Ltd. Announces Closing of Initial Public Offering
    From Adlai Nortye Ltd.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.